Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 34: 890-897, 1988;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cotariu, D.
Right arrow Articles by Zaidman, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cotariu, D.
Right arrow Articles by Zaidman, J. L.

Clinical Chemistry, Vol 34, 890-897, Copyright © 1988 by American Association for Clinical Chemistry

Valproic acid and the liver

D Cotariu and JL Zaidman
Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.

Valproic acid (VPA) is widely used as an anticonvulsant, but therapy with the drug has been associated with hepatotoxicity, either reversible hepatic dysfunction or irreversible hepatic failure. Both clinical and experimental studies have revealed several VPA-related biochemical abnormalities in the liver: inhibition of the beta- oxidation and synthesis of fatty acids and inhibition of gluconeogenesis, urea synthesis, oxidative phosphorylation, and the glycine cleavage system. Other abnormalities noted include alteration in the protein conformation of the internal mitochondrial membrane, hyperammonemia, and increased bile flow. The mechanisms of such hepatotoxicity, whether mediated by VPA or by its metabolites, are still little understood. Susceptibility to VPA hepatotoxicity may be enhanced by such conditions as starvation, inborn errors of metabolism, additional neurological disease, and concomitant administration of enzyme-inducing drugs.


The following articles in journals at HighWire Press have cited this article:


Home page
 Drug Metab. Dispos.Home page
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners
IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION
Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
J Arena, J I Emparanza, A Nogues, and A Burls
Skin to calcaneus distance in the neonate
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2005; 90(4): F328 - f331.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Faiella, M. Wernig, G. G. Consalez, U. Hostick, C. Hofmann, E. Hustert, E. Boncinelli, R. Balling, and J. H. Nadeau
A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression
Hum. Mol. Genet., January 22, 2000; 9(2): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J.-M. Nicolas, P. Collart, B. Gerin, G. Mather, W. Trager, R. Levy, and J. Roba
In Vitro Evaluation of Potential Drug Interactions With Levetiracetam, A New Antiepileptic Agent
Drug Metab. Dispos., February 1, 1999; 27(2): 250 - 254.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Association for Clinical Chemistry.